SANUWAVE Health, Inc. is a medical device company in the United States and internationally. The company is headquartered in Eden Prairie, Minnesota.
| Revenue (TTM) | $44.02M |
| Gross Profit (TTM) | $33.60M |
| EBITDA | $4.26M |
| Operating Margin | -2.88% |
| Return on Equity | 0.00% |
| Return on Assets | 5.51% |
| Revenue/Share (TTM) | $5.13 |
| Book Value | $0.32 |
| Price-to-Book | 6.91 |
| Price-to-Sales (TTM) | 0.43 |
| EV/Revenue | 0.695 |
| EV/EBITDA | 1.52 |
| Quarterly Earnings Growth (YoY) | -99.60% |
| Quarterly Revenue Growth (YoY) | -3.10% |
| Shares Outstanding | $8.60M |
| Float | $6.19M |
| % Insiders | 1.30% |
| % Institutions | 37.38% |
Volatility is currently contracting
EDEN PRAIRIE, Minn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, November 11, 2026, at 8:30 AM (ET) to present its Q3 2026 financial results.
CMS establishes $314.54 reimbursement rate for CPT code 97610 for 2027, an approximately 21% reduction vs 2026 rate of $397.81 2027 Hospital outpatient rate for 97610 code set at $235.04, an approximately 15% increase vs 2026 rate of $204.98 Company evaluating options for continued response EDEN PRAIRIE, Minn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today commented on the Centers for Medicare & Medicaid Services (“CMS”) Calendar Year 2027 Physician Fee Schedule (“PFS”) final rule, released after close of market November 4, 2026.
SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript
Sanuwave Health NASDAQ: SNWV reported second-quarter 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, as lower UltraMIST system sales offset continued growth in the company's recurring applicator business.
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.
EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6 to $9.8 million, above the high end of the revised guidance range of $8.5 to $9.5 million provided in the Company's press release dated June 16, 2026.
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13 of this year.
Sanuwave Health NASDAQ: SNWV reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to the year tied to changes in reimbursement for skin substitutes.
SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM (ET) to present its Q1 2026 financial results.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SNWV and any ticker you trade — then tracks every position and per-strategy win rate.
